Skip to main content
MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED logo

MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · MVP ISIN · AU000000MVP2 LEI · 9845007EAECAOD1U4493 ASX Manufacturing
Open in API
Filings indexed 908 across all filing types
Latest filing 2016-09-21 Notice of Dividend Amou…
Country AU Australia
Listing ASX MVP

About MEDICAL DEVELOPMENTS INTERNATIONAL LIMITED

https://medicaldev.com

Medical Developments International Limited specializes in the development and distribution of emergency pain relief and respiratory products. The company's flagship product is Penthrox, a handheld, self-administered inhaler providing rapid-onset, non-opioid analgesia using methoxyflurane. Penthrox is utilized globally by emergency medical services, hospitals, and for procedural pain in various clinical settings. Additionally, the company manufactures a range of respiratory medical devices, including anti-static spacers and asthma management tools designed to optimize medication delivery. The organization focuses on providing portable, effective solutions for acute pain management and respiratory care, catering to healthcare professionals and patients in emergency, surgical, and primary care environments.

Recent filings

Filing Released Lang Actions
Update - Dividend/Distribution - MVP 4 pages 34.9KB
Notice of Dividend Amount Classification · 100% confidence The document is titled 'Notification of dividend / distribution' and contains detailed information about a dividend payment, including dividend amount, record date, payment date, franking details, and dividend reinvestment plan (DRP) specifics. It is an announcement regarding the dividend amount and related details for shareholders. There is no indication that this is a full financial report or an earnings release; rather, it is a formal notification of dividend payment. Therefore, the document fits the category of 'Notice of Dividend Amount' (DIV). The document length and content confirm it is not merely a brief announcement of a report publication or a regulatory filing, but a substantive dividend notification.
2016-09-21 English
Annual Report to shareholders 70 pages 2.8MB
Annual Report Classification · 95% confidence The document is titled 'Full-Year Report 2016 Financial Year Ended 30 June 2016' and contains detailed financial and operational information for the full fiscal year ending June 30, 2016. It includes comprehensive financial performance data, business highlights, clinical developments, commercial developments, and operational expenses. The length of the document (15,000 characters) and the depth of content indicate it is a full annual report rather than a brief announcement or summary. There is no indication that this is merely an announcement of a report or a certification. The content aligns with the definition of an Annual Report (10-K) which covers company activity and full financial performance for the year.
2016-09-21 English
Notice of Annual General Meeting / Proxy form 11 pages 920.5KB
AGM Information Classification · 100% confidence The document is titled 'Notice of Thirteenth Annual General Meeting' and includes details about the date, location, agenda items such as receiving financial statements, adoption of the remuneration report, and election of directors. It provides procedural information for shareholders about voting, proxies, and meeting conduct. The document does not contain the actual financial statements or reports but rather the notice and explanatory notes for the AGM. This matches the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting. The document length is substantial (15,000 characters), consistent with a detailed AGM notice rather than a brief announcement. Therefore, the correct classification is AGM Information (AGM-R).
2016-09-21 English
MVP signs Licensing Agreement for Penthrox in Canda 2 pages 269.7KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a new exclusive licensing and distribution agreement between Medical Developments International Limited and Purdue Pharma Canada for the product Penthrox in Canada. It contains no financial statements, no regulatory filings, no voting results, no management changes, no earnings data, and no detailed report content. It is a corporate announcement about a business deal related to licensing and distribution, which fits best under Capital/Financing Update (CAP) as it involves milestone and success-based payments and a licensing agreement. The document length is 3618 characters, which is short but contains substantive information about a financing-related agreement rather than just an announcement of a report publication or regulatory filing. Therefore, the best classification is CAP with high confidence.
2016-09-11 English
Penthrox receives regulatory approval in the UAE 2 pages 250.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 9 September 2016 regarding Medical Developments International Limited receiving regulatory approval and Marketing Authorisation for the sale of Penthrox in the UAE. It is a company announcement about regulatory approval and market expansion, not a financial report, earnings release, or management discussion. The document is relatively short (4457 characters) and focuses on a regulatory milestone and business update. It does not contain financial statements, detailed financial analysis, or management commentary on financial results. It is not a report publication announcement since it contains substantive content about the approval. The content fits best under a general regulatory announcement category rather than a specific financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2016-09-08 English
Licensing deal for Korea 2 pages 253.8KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 6 September 2016 about a licensing deal for exclusive distribution rights of a product (Penthrox) in Korea. It discusses the terms of the deal, payments, and strategic partnership details. There are no financial statements, regulatory certifications, voting results, or management changes. The document is relatively short (3673 characters) and serves as a corporate announcement about a commercial agreement rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is a typical corporate announcement about a licensing deal, which aligns best with Capital/Financing Update (CAP) as it involves a transaction with upfront and milestone payments and strategic partnership information.
2016-09-05 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.